PAR1 contributes to influenza A virus pathogenicity in mice
Khoufache, Khaled × Berri, Fatma Nacken, Wolfgang Vogel, Annette B Delenne, Marie Camerer, Eric Coughlin, Shaun R Carmeliet, Peter Lina, Bruno Rimmelzwaan, Guus F Planz, Oliver Ludwig, Stephan Riteau, Béatrice #
American Society for Clinical Investigation
Journal of Clinical Investigation vol:123 issue:1 pages:206-214
Influenza causes substantial morbidity and mortality, and highly pathogenic and drug-resistant strains are likely to emerge in the future. Protease-activated receptor 1 (PAR1) is a thrombin-activated receptor that contributes to inflammatory responses at mucosal surfaces. The role of PAR1 in pathogenesis of virus infections is unknown. Here, we demonstrate that PAR1 contributed to the deleterious inflammatory response after influenza virus infection in mice. Activating PAR1 by administering the agonist TFLLR-NH2 decreased survival and increased lung inflammation after influenza infection. Importantly, both administration of a PAR1 antagonist and PAR1 deficiency protected mice from infection with influenza A viruses (IAVs). Treatment with the PAR1 agonist did not alter survival of mice deficient in plasminogen (PLG), which suggests that PLG permits and/or interacts with a PAR1 function in this model. PAR1 antagonists are in human trials for other indications. Our findings suggest that PAR1 antagonism might be explored as a treatment for influenza, including that caused by highly pathogenic H5N1 and oseltamivir-resistant H1N1 viruses.